BLACK DIAMOND THERAPEUTICS INC. - COMMON STOCK

2.2300

11-February-25 08:31:09

15 minutes delayed

Stocks

0.0000

0.00%

Today's range

2.2300 - 2.2400

ISIN

N/A

Source

NASDAQ

Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 07:00:02 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

08 Nov 2021 15:05:02 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

08 Nov 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

08 Oct 2021 15:05:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

30 Sep 2021 15:35:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

21 Sep 2021 15:05:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform

21 Sep 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

12 Aug 2021 07:22:20 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

10 Aug 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

04 Aug 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

19 May 2021 16:00:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

17 May 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

07 May 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

28 Apr 2021 09:38:27 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

10 Apr 2021 07:30:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

25 Mar 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

10 Mar 2021 15:58:50 By Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

02 Mar 2021 15:05:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

23 Feb 2021 06:45:00 By Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series

11 Feb 2021 15:15:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.